Leonard H. Wexler, MD
Pediatric Hematologist-Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Pediatric Oncology
- Bone and Soft Tissue Sarcomas
- Anthracycline Cardiotoxicity/Cardioprotection
Request an Appointment
About Me
- Attending Pediatrician
I am a pediatric oncologist at MSK Kids with a special interest in treating children, adolescents, and young adults with sarcomas of the bone and soft tissues. These are rare tumors — fewer than 2,000 cases are diagnosed in United States each year. I work with a team of oncologists, pediatric and orthopedic surgeons, and radiation therapists to offer unique expertise and treatment options to patients with both newly diagnosed sarcomas and those that came back after previous treatment.
Read more
I co-directed an international study to evaluate the effectiveness of chemotherapy for children with osteosarcoma, a type of bone cancer. I am leading a clinical trial for children with Ewing’s sarcoma in first relapse which is comparing outcomes with chemotherapy alone versus the same chemotherapy combined with a vaccine developed from a patient’s own tumor.
Some of the chemotherapy drugs that we use to treat children may injure heart tissue. I have been involved in the development and assessment of dexrazoxane, a drug we now routinely use to protect heart tissue in children who are receiving doxorubicin as part of their treatment.
To educate the next generation of physicians, I am one of the lead attending physicians on the faculty-fellow team, which is designed to work closely with young doctors who are training in this subspecialty to help them learn how best to identify the individual needs of patients and manage the care of children with cancer.
Nationally, I have served on the National Comprehensive Cancer Network committee on fatigue in people with cancer. I also serve on Memorial Sloan Kettering’s fertility preservation committee to develop standards to refer patients for counseling and options.
My colleagues and I at MSK Kids form a team of individuals who extend the same family-centered, holistic philosophy of care to our young adult and adult patients as well as our younger pediatric patients. We try to connect with our patients and their families on a very personal level. Many of us maintain relationships with our patients outside of the hospital. I find great satisfaction in attending major life milestones such as weddings, births, Bar Mitzvahs, and confirmations.
Each year, I volunteer my time to work with children at Camp Simcha, a summer camp for children battling cancer. I find it incredibly rewarding to care for children — they are courageous and indomitable. They just want to finish treatment and go back to being kids who play and go to school. I am amazed at the strength of their families during this time as well, and I am as devoted to helping their children get better as if they were my own.
A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).
My Specialties
- Pediatric Oncology
- Bone and Soft Tissue Sarcomas
- Anthracycline Cardiotoxicity/Cardioprotection
- Supportive Care
Education
- MD, Boston University School of Medicine
Residencies
- General Pediatrics - Albert Einstein College of Medicine/Montefiore Medical Center
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2000-2023)
- New York Magazine Top Doctors (2005-2009, 2011-2020)
Fellowships
- Pediatric Hematology/Oncology - National Cancer Institute
Board Certifications
- Pediatrics
- Pediatric Hematology-Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Wexler sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Wexler
- A Phase III Study of Different Treatments for People Newly Diagnosed with Very Low-Risk and Low-Risk Rhabdomyosarcoma
- A Phase III Study to Compare Early Use of Vinorelbine and Maintenance Therapy for People with High-Risk Rhabdomyosarcoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Wexler’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Leonard H. Wexler discloses the following relationships and financial interests:
-
Treeline Biosciences, Inc.
Professional Services and Activities
-
US WorldMeds, LLC.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].